FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/New Study Aims to Compare Adrenalectomy and Semaglutide for Treating Mild Autonomous Cortisol Secretion
Voltar à Biblioteca de Pesquisa

New Study Aims to Compare Adrenalectomy and Semaglutide for Treating Mild Autonomous Cortisol Secretion

November 20, 2026
Share
Pesquisa Emergente

Baseado em pesquisa emergente. Esses achados são promissores, mas requerem validação adicional.

Sobre esta Análise

Este artigo é uma síntese assistida por inteligência artificial de um item noticiário ou lista de ensaios clínicos recentemente publicado. É intenção fornecer uma visão rápida e acessível para a comunidade de pesquisa em peptídeos. Para obter a precisão completa, sempre consulte o

New Study Aims to Compare Adrenalectomy and Semaglutide for Treating Mild Autonomous Cortisol Secretion

A groundbreaking new study launched at the University of Texas Southwestern Medical Center is set to explore the effectiveness of two different treatments—adrenalectomy and semaglutide—in managing mild autonomous cortisol secretion (MACS). This Phase 4 clinical trial, titled "IMPACT-MACS," seeks to provide valuable insights into how these interventions impact insulin resistance, cortisol regulation, body composition, blood pressure, cholesterol levels, inflammation, muscle strength, and overall quality of life in adults with MACS.

Background

Mild autonomous cortisol secretion (MACS) is a condition characterized by the excessive production of cortisol by the adrenal glands without the presence of Cushing's syndrome. This overproduction can lead to various metabolic issues such as insulin resistance, high blood pressure, and changes in body composition. Traditionally, adrenalectomy has been one of the primary surgical options for treating severe cases of MACS or subclinical Cushing’s syndrome. However, with the advent of new medications like semaglutide, which is commonly used to manage weight and diabetes, researchers are exploring non-surgical alternatives that may offer similar benefits without the risks associated with surgery.

The study's focus on comparing adrenalectomy against a medication such as semaglutide highlights an important shift in how medical professionals approach treating MACS. By evaluating these two distinct methods, the research aims to provide clinicians and patients with more informed choices regarding treatment options.

Key Details

The IMPACT-MACS trial is currently recruiting participants who have been diagnosed with mild autonomous cortisol secretion (MACS) or subclinical Cushing’s syndrome. The study will follow a randomized design where half of the participants will undergo adrenalectomy, while the other half will be treated with semaglutide. Researchers will monitor various health markers over an extended period to assess the long-term impacts of both treatments.

The primary objectives of this clinical trial include evaluating changes in insulin resistance and cortisol regulation after treatment. Additionally, secondary outcomes focus on assessing body composition, blood pressure levels, cholesterol profiles, inflammatory responses, muscle strength, and overall quality of life improvements for participants receiving either adrenalectomy or semaglutide therapy.

Key Takeaways

  • Comparative Analysis: The study aims to compare the effectiveness of surgical intervention (adrenalectomy) versus medication (semaglutide) in treating MACS.
  • Comprehensive Health Metrics: Researchers will track a wide range of health indicators, including insulin resistance, cortisol levels, body composition, and quality of life measures.
  • Patient-Centered Approach: By providing insights into both surgical and non-surgical treatment options, the study seeks to empower patients and healthcare providers with more informed decision-making tools.
  • Advancing Peptide Research: This research contributes to the broader understanding of peptide therapy efficacy in managing metabolic disorders.

What This Means

For the peptide community, this clinical trial represents a significant step forward in evaluating non-invasive treatment options for conditions like MACS. As semaglutide and similar peptides continue to demonstrate their potential benefits across various health issues, studies like IMPACT-MACS offer crucial data points that can influence future regulatory decisions and clinical guidelines.

Moreover, the findings from this study could pave the way for further research into how peptide therapies might be used to manage other metabolic disorders. By providing a detailed comparison between surgical and pharmaceutical approaches, researchers hope to uncover new insights that could lead to more personalized treatment plans tailored to individual patient needs.

---

Source: ClinicalTrials.gov — Published 2026-11-18

This article is for informational purposes only and does not constitute medical advice.

Nota do Editor

Esta análise foi gerada usando ferramentas de inteligência artificial e revisada pela equipe editorial da Peptide Contacts. Embora busquemos a precisão, o conteúdo gerado por inteligência artificial pode conter erros ou omissões. Encorajamos os leitores a revisar o fonte original para detalhes completos, metodologia e dados.

A Peptide Contacts fornece resumos de pesquisa curados para fins informativos apenas. Este conteúdo não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.

Comments

Sign in to join the discussion

Este artigo foi gerado usando inteligência artificial e pode conter inaccuracy. É fornecido para fins informativos apenas e não constitui conselhos médicos. Sempre verifique as informações com a fonte original e consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.